A Study to Evaluate the Long-Term Safety of Idecabtagene Vicleucel Treatment in Adults With Newly Diagnosed Multiple Myeloma in Korea
← catalyst calendarNCT06698887 · readout in 1,681 d
Sponsored by Bristol-Myers Squibb (industry) · BMY — their whole pipeline →.
Phase
—
Status
Recruiting
Study type
Observational
Enrollment
15estimated
Sites
5
Country
South Korea
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2024-09-11 | actual | When the study began enrolling |
| Primary completion | 2031-03-27 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2031-03-27 | estimated | The whole study's end, after follow-up |
| First posted | 2024-11-21 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2024-12-13 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Multiple Myeloma
Intervention
- Drug: Idecabtagene vicleucel
Primary outcomes
what the primary-completion date above is the date OFParticipant adverse events
measured Monthly from months 4-18, every 2 months from months 19-59, and annually from month year 5 to 15
Number of participants with positive replication-competent lentivirus test results
measured At 4, 7, 13, and 25 months, and annually up to 15 years
Persistent vector sequence monitoring
measured Months 7-18 and annually from years 5-15
Permalink · BMY's whole pipeline · Catalyst calendar · Every registered study · What changed